Home
About Us

About Us

Company Profile Organization Leadership speech Honor Development course
Industry

Industry

Onofi Pharmaceuticals Spry Pharmaceuticals New Novartis Bio
Innovation

Innovation

Innovation platform R&d team Innovative technology Scientific research achievement
Market

Market

Service concept Chinese market Global market
Products

Products

Chemical products Chinese medicine products API Pharmaceutical Intermediates
Responsibility

Responsibility

Public Welfare Company news Exhibition Information Policies and regulations
Contact

Contact

Contact Us Investor Jobs Message

Language



Development course

2022.8

On August 1, 2022, Huafang Medicine passed the GMP compliance inspection of Anhui Drug Evaluation and Inspection Center and obtained approval (Wanyao Review [2022] No. 71).
2022.7

On July 28, 2022, Hefei Spurui Pharmaceutical Co., Ltd. passed the GMP compliance inspection of Anhui Drug Evaluation and Inspection Center and obtained approval (Wanyao Review [2022] No. 68).
2022.5

On May 16, 2022, the company established Hefei Onofi Pharmaceutical Co., Ltd. as a platform for the industrialization of Huafang medicine.
2022.4

On April 12, 2022, the company submitted the registration application of "Nifedipine controlled release tablets" to the National Drug Evaluation Center.
2021.7

On July 20, 2021, the change of marketing authorization holder obtained the Drug Supplementary Application Approval Notice, and the marketing authorization holder changed from Sinopmedicine Guorui Pharmaceutical Co., Ltd. to Hefei Huafang Pharmaceutical Technology Co., LTD.
2021.6

On June 23, 2021, Venlafaxine hydrochloride sustained release tablets won the bidding in the fifth batch of national centralized drug procurement, and the selected regions included Anhui, Beijing, Tianjin, Guangdong, Hebei, Jilin, Yunnan and Xizang. The first year's purchase volume was 21.07 million tablets, with a supply period of 3 years.
2021.6

In June 2021, the company completed the first round of financing of 30 million yuan. The investment institutions are Hefei New Economy Development Industrial Development Investment Co., LTD and Nanjing Huihang No. 2 Equity Investment Partnership (limited partnership).
2020.12

On December 29, 2020, Venlafaxine hydrochloride sustained release tablets, the company's product, was approved drug registration certificate (National drug approval number: H20203741).
2020.12

On December 1, 2020, the company signed an investment cooperation agreement with the Management Committee of Hefei High-tech Zone. The company plans to invest 310 million yuan to build a new production base of "Research and industrialization of new drug release system" and create a high-end preparation industrialization R&D platform such as osmotic pump.
2020.11

On November 10, 2020, Hefei Novartis Biotechnology Co., Ltd. was changed to a wholly-owned subsidiary of Huafang Medicine.
2019.8

In August 2019, the company built a production platform - Hefei Spurui Pharmaceutical Co., Ltd.
2016.9

On September 28, 2016, Xinruihua Equity Investment Partnership (Limited Partnership) was established as an employee stock ownership platform.
2014.9

In September 2014, the company's registered capital increased from 1 million yuan to 8 million yuan.
2014.6

In June 2014, the company moved into the Science and Technology Industrial Park of Hefei National High-tech Zone, invested more than 20 million yuan, and established a "new drug research and development center", with an area of 3300m² for independent property research and development and office space.
2007.1

In January 2007, the company moved into the science and technology incubator of Hefei National High-tech Industrial Development Zone - Huayi Science Park, with an area of 800m².
2003.12

On December 1, 2003, the company was established and settled in Anhui University Science and Technology Park, Hefei National High-tech Industrial Development Zone, with a registered capital of 200,000 yuan and an area of 300m². It is a high-tech enterprise for new drug research and development with independent legal personality.